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Insulin After 75 Years: Still A Heroic Hormone 
is year marks the 75th anniversary of the discovery of 
first reported their success in preparing a pancreas extract 
that dramatically lowered blood glucose levels in diabetic 
dogs in early 1922.' As early as the Spring of 1922, remark- 
ably fast time by today's standards, this achievement was 
followed by successful clinical trials in humans that demon- 
strated the effectiveness of the pancreas extract in lowering 
glucose levels and preventing death from diabetic ketoacido- 
sis. Indeed, one of the early patients treated with this extract 
survived for 59 years and another for more than 70 years: 
some outcomes for a clinical trial! Banting and Best subse- 
quently won the Nobel Prize for this work. 
In medical school we learn about the remarkable powers 
of this heroic hormone, insulin, which turned out to be the 
active ingredient in the pancreas extract. Insulin, a lone 
anabolic hormone, does battle with multiple catabolic hor- 
mones such as glucocorticoids, glucagon, and catecholamines 
to maintain homeostatic balance. In the hospital we observe 
directly insulin's power to reverse the dramatic metabolic 
derangements of patients presenting with diabetic ketoacido- 
sis. 
T" insulin. Banting and Best at the University of Toronto 
See also D 407 
With this as background, as an insulinophile I have been 
somewhat shocked and disturbed by a number of epidemio- 
logical studies suggesting that elevated levels of this wonder- 
ful hormone insulin may be detrimental, a marker or inde- 
pendent risk factor for the development of coronary artery 
disease.2 However, increased insulin levels occurring as a 
physiological response to insulin resistance are associated 
with a number of other metabolic abnormalities, including 
hypertension, central body adiposity, and lipid abnormali- 
ties3 When these other known risk factors for coronary 
artery disease are controlled for, evidence for an independent 
adverse effect of insulin has not been very con~istent.~. 
Recently, a study of men from Quebec, using a matched pair 
design to control for other risk factors, again suggested that 
hyperinsulinemia independently predicts development of cor- 
onary artery disease. Thus, it was with some relief that I read 
the paper by Lindberg, et al. in the current issue of thelournal 
of the American Geriatrics Society indicating that in cohorts 
of older Finnish men, prospective follow-up demonstrated no 
adverse effect of a higher insulin level on either development 
of coronary heart disease or survival '. In fact, there is a 
suggestion of better survival in those with higher insulin 
levels, a bonus finding for an insulinophile like me. Although 
patients in this study who have cardiovascular disease cross- 
sectionally tend to have higher insulin levels, the authors 
conclude that this elevation of insulin is secondary to the 
cardiovascular disease rather a contributing factor. 
A number of investigators have developed a rationale for 
potential adverse effects of increased insulin levels. Insulin 
has direct cardiovascular effects,* some of which could con- 
tribute to the development of hypertension, which in turn 
causes coronary artery disease. Insulin can also lead to alter- 
ations of lipid metabolism and is reported to have poten- 
tially atherogenic effects on vascular smooth muscle in 
vitro." 
After 75 years, where do we stand regarding benefits and 
potential risks of insulin? Epidemiologists sometimes de- 
scribe J-shaped curves in predictions of mortality. For exam- 
ple, Andres has demonstrated that although increasing adi- 
posity is associated with increased mortality, there is also an 
association of diminished adiposity with increasing mortality 
such that the degree of adiposity for best survival lies between 
low and high." Perhaps the relationship between insulin and 
coronary artery disease or mortality is a reversed J. It is very 
clear that marked insulin deficiency is a direct cause of death 
and that insulin-deficient people with diabetes are at substan- 
tially increased risk for development of coronary artery dis- 
ease and other diabetes complications." Although insulin 
resistance is present in patients with diabetes mellitus, partic- 
ularly NIDDM, these patients with overt hyperglycemia have 
beta cell failure and low rather than high insulin 1e~els.I~ t 
should also be noted that a number of previous studies have 
overestimated circulating insulin levels in people with diabe- 
tes because commonly used insulin assays measure both 
insulin and proinsulin, and there is now evidence that pa- 
tients with overt diabetes have an increased percentage of 
circulating pr0insu1in.l~ Thus, there is little doubt that low 
insulin levels are associated with adverse outcomes. There 
may also be a small increased risk associated with chronic 
exposure to elevated insulin levels as occurs in people with 
insulin resistance (but not diabetes). However, this remains 
controversial and may be explained by a number of other risk 
factors that are associated with insulin resistance but not 
caused by it. At least among Finnish men who have survived 
to the geriatric age cohort, increased circulating insulin levels 
may be a better marker of survival than of adverse events. 
Further conclusions about potential risks of hyperinsulin- 
emia in other populations and in women will await addi- 
tional studies. In the meantime, let's celebrate the 75th anni- 
versary of the discovery of insulin with the enthusiasm that it 
deserves. 
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